Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer

by Jennifer D. Brooks, Esther M. John, Lene Mellemkjær, Charles F. Lynch, Julia A. Knight, Kathleen E. Malone, Anne S. Reiner, Leslie Bernstein, Xiaolin Liang, Roy E. Shore, Marilyn Stovall, WECARE Study Collaborative Group, Jonine L. Bernstein
Published 2016-11-01

The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study

by Julia A. Knight, Kristina M. Blackmore, Jing Fan, Kathleen E. Malone, Esther M. John, Charles F. Lynch, Celine M. Vachon, Leslie Bernstein, Jennifer D. Brooks, Anne S. Reiner, Xiaolin Liang, Meghan Woods, WECARE Study Collaborative Group, Jonine L. Bernstein
Published 2018-03-01

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

by Jennifer D. Brooks, Elizabeth A. Comen, Anne S. Reiner, Irene Orlow, Siok F. Leong, Xiaolin Liang, Lene Mellemkjær, Julia A. Knight, Charles F. Lynch, Esther M. John, Leslie Bernstein, Meghan Woods, David R. Doody, The WECARE Study collaborative group, Kathleen E. Malone, Jonine L. Bernstein
Published 2018-12-01

Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

by Anne S. Reiner, Charles F. Lynch, Julia S. Sisti, Esther M. John, Jennifer D. Brooks, Leslie Bernstein, Julia A. Knight, Li Hsu, Patrick Concannon, Lene Mellemkjær, Marc Tischkowitz, Robert W. Haile, Ronglai Shen, Kathleen E. Malone, Meghan Woods, Xiaolin Liang, Monica Morrow, Jonine L. Bernstein, on behalf of WECARE Study Collaborative Group
Published 2017-07-01